Disclosures for "Strokes in Individuals with Primary Brain Glioma After Radiation Therapy Managed with Bevacizumab: A Subgroup Analysis of a Retrospective Cohort "
-
Dr. Ryan has nothing to disclose.
-
Dr. Sugita has nothing to disclose.
-
Eric Lipp, 10512 has nothing to disclose.
-
Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sapience. Dr. Peters has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NuVox Therapeutics. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ONO Pharmaceutical. The institution of Dr. Peters has received research support from Novocure. The institution of Dr. Peters has received research support from Biomimetix. The institution of Dr. Peters has received research support from Servier. The institution of Dr. Peters has received research support from Varian. The institution of Dr. Peters has received research support from Sapience. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving as a Educational Lecturer with Eisai.
-
The institution of Dr. El Husseini has received research support from the DISCOVERY trial funded by the National Institute of Neurological Disorders and Stroke (NINDS)and the National Institute on Aging (NIA) (U19NS115388).- subcontract from MGH.